Detalles de la búsqueda
1.
A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin.
Invest New Drugs
; 33(6): 1187-96, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26403509
2.
Pharmacokinetics, metabolism, and excretion of the glycogen synthase kinase-3 inhibitor LY2090314 in rats, dogs, and humans: a case study in rapid clearance by extensive metabolism with low circulating metabolite exposure.
Drug Metab Dispos
; 41(4): 714-26, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23305709
Resultados
1 -
2
de 2
1
Próxima >
>>